Future Health ESG in a proxy filing seeks shareholder approval to extend its completion deadline to Dec. 31, 2024. The SPAC raised $200 million in a September 2021 IPO to target businesses that support value-based precision healthcare.
Shareholders a year ago approved the SPAC’s first extension, when 18,408,463 shares were redeemed. That erased approximately $187 million from the trust. Just under $17 million remains in trust as of Sept. 30.
The proxy also outlines a non-redemption incentive under which shareholders who hold their stock to completion of a merger would receive one newly issued share in the combined company for each share they own.
The SPAC in November 2022 terminated a merger agreement with Excelera Health. Read more.
